ArticleJNCI cancer spectrum2018
Comparing Survival After Recurrent vs De Novo Stage IV Advanced Breast, Lung, and Colorectal Cancer.
Article in JNCI cancer spectrum, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Integrating a Shareable Artificial Intelligence Model Into Clinical Research for Cancer Recurrence in Patients With Breast and Colorectal Cancer.JCO clinical cancer informatics · 2025Article
- Unveiling non-small cell lung cancer treatment effect heterogeneity: a comparative analysis of statistical methods.Journal of the National Cancer Institute · 2025Article
- Patterns of recurrence among adults diagnosed with screen-detected lung cancer.Cancer epidemiology · 2025Article
- Benefits from early trial involvement in metastatic colorectal cancer: outcomes from the phase I unit at the Sarah Cannon Research Institute UK.ESMO gastrointestinal oncology · 2024Article
- Treatment Patterns and Health Outcomes among Patients with HER2 IHC0/-Low Metastatic or Recurrent Breast Cancer.Cancers · 2024Article
- Overall Survival Among Patients With De Novo Stage IV Metastatic and Distant Metastatic Recurrent Non-Small Cell Lung Cancer.JAMA network open · 2023Article
- Smoking status and the association between patient-level factors and survival among lung cancer patients.Journal of the National Cancer Institute · 2023Article
- Unravelling oligometastatic disease from the perspective of radiation and medical oncology. Part I: non-small cell lung cancer and breast cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2023Article
- Cancer Survivorship and Supportive Care Economics Research: Current Challenges and Next Steps.Journal of the National Cancer Institute. Monographs · 2022Review
- Impact of the COVID-19 Pandemic on Treatment Patterns for Patients With Metastatic Solid Cancer in the United States.Journal of the National Cancer Institute · 2022Article
- Regarding the Utility of Unstructured Data and Natural Language Processing for Identification of Breast Cancer Recurrence.JCO clinical cancer informatics · 2021Article
- Characteristics and survival of de novo and recurrent metastatic breast cancer in New Zealand.Breast cancer (Tokyo, Japan) · 2021Article
- Estimating Population-Based Recurrence Rates of Colorectal Cancer over Time in the United States.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2020Article
- Cost-effectiveness of surveillance with CT colonography after resection of colorectal cancer.BMJ open gastroenterology · 2020Article
- Performance of Cancer Recurrence Algorithms After Coding Scheme Switch From International Classification of Diseases 9th Revision to International Classification of Diseases 10th Revision.JCO clinical cancer informatics · 2019Article
- Does Stage at Diagnosis Affect Prognosis of Patients With Stage IV Breast, Lung, and Colorectal Cancers?JNCI cancer spectrum · 2018Article
Corrections and comments
- Commented on by
Authors and funding
6 authors.
Funding
Abstract
The treatments provided to and survival of patients with recurrent vs de novo stage IV advanced breast, lung, and colorectal cancer may differ but have not been well studied. Using population-based data from the Cancer Research Network for 4510 patients with advanced breast, lung, or colorectal cancer, we matched recurrent/de novo patients on demographic factors. We found longer survival for recurrent vs de novo lung cancer (182 matched pairs); no significant difference for colorectal cancer (332 matched pairs); and shorter survival for recurrent vs de novo breast cancer (219 matched pairs). Compared with recurrent cases, chemotherapy use and radiation therapy use were more common among de novo cases. Differences in treatment and survival between recurrent and de novo advanced cancer patients could inform prognostic estimates and clinical trial design.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.